Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7806881 in Healthy Participants
NCT07271693Phase 1Recruiting
- Sponsor
- Roche
- Start
- Dec 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RO7806881 (4 arms), sponsored by Roche. Primary endpoints: Number of Participants With Adverse Events and Number of Participants With Dose-limiting Adverse Events. Started Dec 2025; status: recruiting.
02
Drugs
RO7806881
Beyond the preview
Go deeper on NCT07271693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07271693.